Dr. Stewart B Harris Peer Reviewed Publications

Monteith H, Mamakeesick M, Rae J, Galloway T, Harris SB, Birken C, Hamilton J, Maguire JL, Parkin P, Zinman B, Hanley AJG. Determinants of Anishinabeck infant and early childhood growth trajectories in Northwestern Ontario, Canada: a cohort study. BMC Pediatr. 2023 Dec 19;23(1):641. doi: 10.1186/s12887-023-04449-5.

Ratzki-Leewing A, Black JE, Kahkoska AR, Ryan BL, Zou G, Klar N, Timcevska K, Harris SB. Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States).  Diabetes Obes Metab. 2023 Dec;25(12):3736-3747. doi: 10.1111/dom.15268. Epub 2023 Sep 13.

Semnani-Azad Z, Wang WZN, Cole DEC, Johnston LW, Wong BYL, Fu L, Retnakaran R, Harris SB, Hanley AJ. Urinary Vitamin D Binding Protein: A Marker of Kidney Tubular Dysfunction in Patients at Risk for Type 2 Diabetes. J Endocr Soc. 2024 Jan 31;8(3):bvae014. doi: 10.1210/jendso/bvae014. eCollection 2024 Jan 16. PMID: 3835296.

Stanimirovic A, Francis T, Webster‑Bogaert S, Harris S, and Rac V on behalf of the LIONESS study group. The TransFORmation of IndiGEnous PrimAry HEAlthcare Delivery (FORGE AHEAD): economic analysis. Health Res Policy Syst, 2024 May 13;22(1):57. doi: 10.1186/s12961-024-01135-5. PMID: 38741196.

Szafranski K, De Pouvourville G, Greenberg D, Harris S, Jendle J, Shaw JE, Coaquira Castro J, Poon Y, Levrat-Guillen F. The DEDUCE Model, A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation. Value Health. 2024 Jan 31:S1098-3015(24)00039-1. doi: 10.1016/j.jval.2024.01.010.

Black JE, Harris SB, Ryan BL, Zou G, Ratzki-Leewing A. Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US).Diabetes Ther. 2023 Jun 3. doi: 10.1007/s13300-023-01423-3. Online ahead of print. PMID: 37270453.

Cheng AY, Goldenberg R, Krawchenko I, Tytus R, Hahn J, Liu A, Golden S, Millson B, Harris S. Impact of the COVID-19 Pandemic on Antihyperglycemic Prescriptions for Adults with Type 2 Diabetes in Canada: A Cross-Sectional Study. Can J Diabetes. 2023 Mar 21:S1499-2671(23)00056-4. Doi: 10.1016/j.jcjd.2023.03.001. Online ahead of print.

Fournie M, Sibbald SL, Harris SB. Exploring quality improvement for diabetes care in First Nations communities in Canada: a multiple case study. BMC Health Serv Res. 2023 May 9;23(1):462. doi: 10.1186/s12913-023-09442-3.PMID: 37161499.

Harris SB, Levrat-Guillen F. Use the FreeStyle Libre system and diabetes treatment progression in T2DM: Results from a retrospective cohort study using a Canadian private payer claims database Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15025. Online ahead of print. setting in Ontario, Canada: A cross-sectional study. Can J Diabetes, Jan 2023 (in press).

Harris SB, Mohammedi K, Bertolini M, White J, Walker V, Zhou FL, Anderson J, Seufert J. Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes Obesity and Metabolism. 12 Jan 2023. DOI: 10.1111/dom.14973 ONLINE ahead of print.

Lai KZH, Semnani-Azad Z, Boucher BA, Retnakaran R, Harris SB, Malik V, Bazinet RP, Hanley AJ. Association of serum very long-chain saturated fatty acids with changes in insulin sensitivity and beta-cell function: the PROspective Metabolism and Islet cell Evaluation (PROMISE) cohort.
Diabetes. 2023 Aug 16:db221050. doi: 10.2337/db22-1050. Online ahead of print. PMID: 37586083.

McInnes N, Hall S, Lochnan HA, Harris SB, Punthakee Z, Sigal RJ, Hramiak I, Azharuddin M, Liutkus JF, Yale JF, Sultan F, Smith A, Otto RE, Sherifali D, Liu YY, Gerstein HC; Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial. REMIT-iGlarLixi Collaborative Group. Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15234. Online ahead of print. PMID: 37580972.

Ratzki-Leewing AA, Black JE, Ryan BL, Zou G, Klar N, Webster-Bogaert S, Timcevska K, Harris SB. Development and validation of a real-world model to predict 1-year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States). Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15186. Online ahead of print. PMID: 37409569.

Retnakaran R, Pu J, Emery A, Harris SB, Reichert SM, Gerstein HC, McInnes N, Kramer CK, Zinman B. Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes. Nat Commun. 2023 Jul 27;14(1):4514. doi: 10.1038/s41467-023-40287-w. PMID: 37500612 Free PMC article. Clinical Trial.

Yehia NA, Isai L, Semnani-Azad Z, Lai KZH, Retnakaran R, Harris SB, Beaudry JL, Bazinet RP, Hanley AJ. Association of circulating branched chain fatty acids with insulin sensitivity and beta cell function in the PROMISE cohort. Lipids. 2023 May 11. doi: 10.1002/lipd.12373. Online ahead of print. PMID: 37165723.

Harris SB, Idzik S, Boasso A, Neunie SQ, Noble AD, Such HE, Van J. The Educational Impact of Online, Faculty-Led Continuing Medical Education Programs in Type 2 Diabetes: An Analysis of Changes in the Knowledge, Competence, and Performance of Healthcare Professionals. JMIR Med Educ. 2022 Oct 14;8(4):e40520.Doi: 10.2196/40520.

Harris SB, Parente EB, Karalliedde J. Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies. Diabetes Ther. 2022 Mar 30. doi: 10.1007/s13300-022-01247-7. Epub ahead of print.  

Hramiak I, Gerstein HC, Leiter LA, Yale JF, Bajaj HS, Stewart J, Toutounji MJ, Harris SB.  Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Diabetes Obes Metab. 2022 Oct. 24(10):1998-2007. doi: 10.1111/dom.14787. Epub 2022 Jun 29.

Khunti K, Aroda VR, Aschner P, Chan JCN, Del Prato S, Hambling CE, Harris S, Lamptey R, McKee M, Tandon N, Valabhji J, Seidu S. The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery. Lancet Diabetes Endocrinol. 2022 Nov 7:S2213-8587(22)00278-9. doi: 10.1016/S2213-8587(22)00278-9. Online ahead of print.

Ratzki-Leewing A, Ryan BL, Zou G, Webster-Bogaert S, Black JE, Stirling K, Timcevska K, Khan N, Buchenberger JD, Dickens JW, Harris SB. Predicting real-world hypoglycemia risk in American adults with type 1 or 2 diabetes mellitus prescribed insulin and/or secretagogues: Protocol for a prospective, 12-wave internet-based panel survey with email support (the iNPHORM study, USA). JMIR Res Protoc. 2022 Jan 6. doi: 10.2196/33726. Epub ahead of print.

Ratzki-Leewing A, Black JE, Ryan BL, Harris SB. Real-world risk factors of confirmed or probable COVID-19 in Americans with diabetes: A prospective, community-based study (iNPHORM). Endocrinol Diabetes Metab. 2022 May 29:e342. doi: 10.1002/edm2.342. Epub ahead of print.

Rebicki CVM, Ryan BL, Ratzki-Leewing A, Tremblay PF, Harris SB. Family Physician Clinical Inertia in Managing Hypoglycemia. Prim Care Diabetes. 2022 Feb 24:S1751-9918(22)00034-1. doi: 10.1016/j.pcd.2022.02.005. Epub ahead of print.

Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes. 2022 Feb 16:S1751-9918(22)00031-6. doi: 10.1016/j.pcd.2022.02.002. Epub ahead of print.  

Yale J.-F.; de Climens A.R.; Aggarwal N.; Dex T.; Gerstein H.C.; Harris S.; Hramiak I.; Stewart J.; Leiter L.A. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes Therapy. 2023 Feb;14(2):377-386. doi: 10.1007/s13300-022-01353-6. Epub 2022 Dec 27.

Brown JB, Valliere Y, McLachlan C, Reichert SM, Webster-Bogaert S, Ratzki-Leewing A, Ryan BL, Harris SB. Beyond the Sick Role: The Many Roles of Adults With Type 1 and Type 2 Diabetes in the Management of Hypoglycemia-The InHypo-DM Study, Canada. Can J Diabetes. 2020 Apr 9:S1499-2671(20)30084-8. doi: 10.1016/j.jcjd.2020.03.011. Epub ahead of print.

Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, Lauand F, Melas-Melt L, Westerbacka J, Bosnyak Z, Rosenstock J. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes Obes Metab. 2020 Mar;22(3):346-354. doi: 10.1111/dom.13901. Epub 2019 Dec 20.

Cos X, Seidu S, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. Impact on guidelines: the general practitioner point of view. Diabetes Res Clin Pract. 2020 Feb 24:108091. doi: 10.1016/j.diabres.2020.108091. Epub ahead of print.

Harris SB, Abrahamson MJ, Ceriello A, Charpentier G, Evans M, Lehmann R, Liebl A, Linjawi S, Holt RIG, Hosszúfalusi N, Rutten G, Vilsbøll T. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs. 2020 Jan 20. doi: 10.1007/s40265-019-01245-3. Epub ahead of print.

Hayward MN, Pace R, Zaran H, Dyck R, Hanley AJ, Green ME, Bhattacharyya O, Zwarenstein M, Emond J, Benoit C, Jebb ML, Harris SB; FORGE AHEAD Program Team. Closing the indigenous health gap in Canada: Results from the TransFORmation of IndiGEnous PrimAry HEAlthcare delivery (FORGE AHEAD) program. Diabetes Res Clin Pract. 2020 Feb 8;162:108066. doi: 10.1016/j.diabres.2020.108066. Epub ahead of print.

Khunti K, Giorgino F, Berard L, Mauricio D, Harris SB. The importance of the initial period of basal insulin titration in people with diabetes. Diabetes Obes Metab. 2020 May;22(5):722-733. doi: 10.1111/dom.13946. Epub 2020 Jan 19.

McInnes N, Hall S, Sultan F, Aronson R, Hramiak I, Harris S, Sigal RJ, Woo V, Liu YY, Gerstein HC. Remission of type 2 diabetes following a short-term intervention with insulin glargine, metformin and dapagliflozin. J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa248. doi: 10.1210/clinem/dgaa248. 

Pace R, Harris SB, Parry M, Zaran H; Transformation of Indigenous Primary Healthcare Delivery (FORGE AHEAD) Program Collaborators. Primary and Secondary Cardiovascular Prevention Among First Nations Peoples With Type 2 Diabetes in Canada: Findings From the FORGE AHEAD Program. CJC Open. 2020 Jul 9;2(6):547-554. doi: 10.1016/j.cjco.2020.07.004

Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, Neijens AMJ, Topsever P, Khunti K. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Prim Care Diabetes. 2020 Jun 9:S1751-9918(20)30189-3. doi: 10.1016/j.pcd.2020.05.004. Epub ahead of print. 

Semnani-Azad Z, Connelly PW, Johnston LW, Retnakaran R, Harris SB, Zinman B, Hanley AJ. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e290–8. doi: 10.1210/clinem/dgz166. Epub Nov 2019.

Wilk P, Ali S, Anderson KK, Clark AF, Cooke M, Frisbee SJ, Gilliland J, Haan M, Harris S, Kiarasi S, Maltby A, Norozi K, Petrella R, Sarma S, Singh SS, Stranges S, Thind A. Geographic variation in preventable hospitalisations across Canada: a cross-sectional study. BMJ Open. 2020 May 15;10(5):e037195. doi: 10.1136/bmjopen-2020-037195.

Zhu NA, Harris SB. Therapeutic Inertia in People With Type 2 Diabetes in Primary Care: A Challenge That Just Won't Go Away. Diabetes Spectr. 2020 Feb;33(1):44-49. doi: 10.2337/ds19-0016. 

Zhu NA, Reichert S, Harris SB. Limitations of hemoglobin A1c in the management of type 2 diabetes mellitus. Can Fam Physician. 2020 Feb;66(2):112-14.

Anand SS, Abonyi S, Arbour L, Balasubramanian K, Brook J, Castleden H, Chrisjohn V, Cornelius I, Davis AD, Desai D, de Souza RJ, Friedrich MG, Harris S, Irvine J, L'Hommecourt J, Littlechild R, Mayotte L, McIntosh S, Morrison J, Oster RT, Picard M; Pictou Landing First Nation, Poirier P, Schulze KM, Toth EL; Canadian Alliance for Healthy Hearts and Minds First Nations Research Group. Explaining the variability in cardiovascular risk factors among First Nations communities in Canada: a population-based study. Lancet Planet Health. 2019 Dec;3(12):e511-e520. doi: 10.1016/S2542-5196(19)30237-2. 

Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C. Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. Diabetes Ther. 2019 Feb:10(1):177-188. doi: 10.1007/s13300-018-0553-7. Epub 2018 Dec 13. 

Brown JB, Reichert SM, Valliere Y, Webster-Bogaert S, Ratzki-Leewing A, Ryan BL, Harris SB. Living With Hypoglycemia: An Exploration of Patients' Emotions: Qualitative Findings From the InHypo-DM Study, Canada. Diabetes Spectr. 2019 Aug;32(3):270-276. doi: 10.2337/ds18-0074. 

Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, Lauand F, Melas-Melt L, Westerbacka J, Bosnyak Z, Rosenstock J. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with Gla-300 vs IDeg-100: a subanalysis of the BRIGHT study. Diabetes Obes Metab. 2019 Oct 23. doi: 10.1111/dom.13901. [Epub ahead of print]. 

Frier BM, Ratzki-Leewing A, Harris SB. Reporting of hypoglycaemia in clinical trials of basal insulins: a need for consensus. Diabetes Obes Metab. 2019 Jul;21(7):1529-1542. doi: 10.1111/dom.13732. Epub 2018 Apr 29.

Khunti K, Giorgino F, Berard L, Mauricio D, Harris SB. The importance of the initial period of basal insulin titration in people with diabetes. Diabetes Obes Metab. 2019 Dec 22. doi: 10.1111/dom.13946. [Epub ahead of print] Review. 

Leiter LA, Cheng AYY, Ekoé JM, Goldenberg RM, Harris SB, Hramiak IM, Khunti K, Lin PJ, Richard JF, Senior PA, Yale JF, Goldin L, Tan MK, Langer A. Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. Can J Diabetes. 2019 Aug:43(6):384-391. doi: 10.1016/j.jcjd.2018.10.005. Epub 2018 Nov 2. 

Philis-Tsimikas A, Billings LK, Busch R, Morales Portillo C, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S. Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes. Diabetes Obes Metab. 2019 June:21(6):1399-1408. doi: 10.1111/dom.13666. Epub 2019 Apr 4. 

Ratzki-Leewing A, Parvaresh Rizi E, Harris SB. Family Members: The Forgotten Players in the Diabetes Care Team (The TALK-HYPO Study). Diabetes Ther. 2019 Dec;10(6):2305-2311. doi: 10.1007/s13300-019-00687-y. Epub 2019 Sep 9. 

Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB. Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 2019 Aug;42(8):1604. doi: 10.2337/dc19-er08. Epub 2019 Jun 21. Diabetes Care 2018;41:1672-1680. 

Santaren ID, Bazinet RP, Liu Z, Johnston LW, Sievenpiper JL, Giacca A, Retnakaran R, Harris SB, Zinman B, Hanley AJ. The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort. Lipids. 2019 Oct;54(10):617-627. doi: 10.1002/lipd.12185. Epub 2019 Aug 19. 

Semnani-Azad Z, Johnston LW, Lee C, Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJ. Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort.  BMJ Open Diabetes Res Care. 2019 Nov 24;7(1):e000825. doi: 10.1136/bmjdrc-2019-000825. eCollection 2019. 

Semnani-Azad Z, Connelly PW, Johnston LW, Retnakaran R, Harris SB, Zinman B, Hanley AJ. The macrophage activation marker soluble CD163 is longitudinally associated with insulin sensitivity and β-cell function. J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz166. doi: 10.1210/clinem/dgz166. [Epub ahead of print] 

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 investigators. Efficacy, Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin ± Metformin in Patients with Type 2 Diabetes: the PIONEER 8 Trial. Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.

Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018 Nov;35(11):1763-1774. doi: 10.1007/s12325-018-0805-y. Epub 2018 Oct 24.

Berard L, Antonishyn N, Arcudi K, Blunden S, Cheng A, Goldenberg R, Harris S, Jones S, Mehan U, Morrell J, Roscoe R, Siemens R, Vallis M, Yale JF. Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. Diabetes Ther. 2018 Apr:9(2):501-519. doi: 10.1007/s13300-018-0375-7. Epub 2018 Feb 23.

Brown JB, Reichert SM, Valliere Y, Webster-Bogaert S, Ratzki-Leewing A, Harris SB. A qualitative enquiry of hypoglycemia and the social determinants of health: The InHypo-DM study, Canada. Fam Syst Health. 2018 Dec:36(4):471-481. doi: 10.1037/fsh0000355. Epub 2018 Jul 12.

Anand SS, Abonyi S, Arbour L, Brook J, Bruce S, Castleden H, Desai D, de Souza RJ, Harris S, Irvine J, Lai C, Lewis D, Oster RT, Poirier P, Toth EL, Bannon K, Chrisjohn V, Davis AD, L'Hommecourt J, Littlechild R, McMullin K, McIntosh S, Morrison J, Picard M, Landing First Nation P, M Thomas M, Tusevljak N, Friedrich MG, Tu JV. Canadian Alliance for Healthy Hearts and Minds: First Nations Cohort Study Rationale and Design. Prog Community Health Partnersh. 2018;12(1):55-64. doi: 10.1353/cpr.2018.0006.

Ratzki-Leewing A, Harris SB, Mequanint S, Reichert SM, Brown JB, Black JE, Ryan BL. Real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM Study, Canada. BMJ Open Diabetes Res Care. 2018 Apr 24;6(1):e000503. doi: 10.1136/bmjdrc-2017-000503. eCollection 2018.

Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 2018 Aug;41(8):1672-1680. doi: 10.2337/dc18-0168. Epub 2018 Jun 12.

Johnston LW, Harris SB, Retnakaran R, Giacca A, Liu Z, Bazinet RP, Hanley AJ. Association of NEFA composition with insulin sensitivity and beta cell function in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort. Diabetologia. 2018 Apr;61(4):821-830. doi: 10.1007/s00125-017-4534-6. Epub 2017 Dec 24.

Tompkins JW, Mequanint S, Barre DE, Fournie M, Green ME, Hanley AJ, Hayward MN, Zwarenstein M, Harris SB; FORGE AHEAD Program Team. National Survey of Indigenous primary healthcare capacity and delivery models in Canada: the TransFORmation of IndiGEnous PrimAry HEAlthcare delivery (FORGE AHEAD) community profile survey. BMC Health Serv Res. 2018 Nov 1;18(1):828. doi: 10.1186/s12913-018-3578-8.

Johnston LW, Liu Z, Retnakaran R, Zinman B, Giacca A, Harris SB, Bazinet RP, Hanley AJ. Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes. Lipid Res. 2018 Sep;59(9):1751-1762. doi: 10.1194/jlr.P084970. Epub 2018 Jul 9.

Lingvay I, Harris SB, Jaeckel E, Chandarana K, Ranthe MF, Jódar E. IDegLira was effective across a range of dysglycaemia and BMI categories in the DUAL V randomized trial. Diabetes Obes Metab. 2018 Jan:20(1):200-204. doi: 10.1111/dom.13043. Epub 2017 Jul 31.